ROLE OF PLATELET-ACTIVATING-FACTOR IN HEMODYNAMIC DERANGEMENTS IN AN ACUTE RODENT PANCREATIC MODEL

被引:26
作者
AIS, G
LOPEZFARRE, A
GOMEZGARRE, DN
NOVO, C
ROMEO, JM
BRAQUET, P
LOPEZNOVOA, JM
机构
[1] CSIC,FDN JIMENEZ DIAZ,MED RES INST,MADRID 6,SPAIN
[2] INST HENRY BEAUFOUR,LE PLESSIS ROBINS,FRANCE
[3] UNIV SALAMANCA,FAC MED,DEPT PHYSIOL & PHARMACOL,AVE CAMPO CHARRO S-N,E-37007 SALAMANCA,SPAIN
关键词
D O I
10.1016/0016-5085(92)91799-A
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Systemic hemodynamics were assessed in a model of experimental pancreatitis induced in rats by the retrograde injection of sodium deoxycholate, 40%, 1 mL/kg, in the pancreatic duct, using the radioactive microsphere technique before and 25 minutes after pancreatitis induction while blood pressure was stable (n = 10). A 55% decrease in cardiac output, a 14% decrease in heart rate, and a 3.3-fold increase in total peripheral resistances, without significant changes in blood pressure, were observed. Renal blood flow decreased by 68%. When rats were given BN-52021, a blocker of platelet-activating factor receptors (5 mg/h, IV; n = 13) coinciding with pancreatitis induction, no significant hemodynamic changes were observed. Animals treated with BN-52021 survived 89 ± 10 minutes, whereas death occurred 67 ± 5 minutes after pancreatitis induction in untreated rats (P < 0.001). A different group of rats with pancreatitis showed higher blood levels of platelet-activating factor (0.28 ± 0.06 ng/ mL; n = 11) than control rats (0.16 ± 0.03; n = 15; P < 0.05). Very high levels of platelet-activating factor were found in peritoneal exudate from rats with pancreatitis. These data show an effective protective effect of BN-52021 on the hemodynamic impairment that follows pancreatitis induction, as well as a role of platelet-activating factor in these alterations. © 1992.
引用
收藏
页码:181 / 187
页数:7
相关论文
共 29 条
[1]  
ANDERSON M C, 1981, ANN SURG, V194, P85
[2]  
ARRIBA G, 1987, NEPHROL DIAL TRANSPL, V2, P123
[3]   ATRIAL-NATRIURETIC-PEPTIDE INHIBITS GLOMERULAR CONTRACTION INDUCED BY ANGIOTENSIN-II AND PLATELET-ACTIVATING-FACTOR [J].
BARRIO, V ;
DEARRIBA, G ;
LOPEZNOVOA, JM ;
RODRIGUEZPUYOL, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 135 (01) :93-96
[4]  
BOURLAND WA, 1982, AM SURGEON, V48, P369
[5]  
BRAQUET P, 1987, PHARMACOL REV, V39, P97
[6]   POTENTIAL ROLE OF PLATELET-ACTIVATING-FACTOR IN RENAL PATHOPHYSIOLOGY [J].
CAMUSSI, G .
KIDNEY INTERNATIONAL, 1986, 29 (02) :469-477
[7]   PRESENCE OF PLATELET-ACTIVATING FACTOR IN BLOOD FROM HUMANS AND EXPERIMENTAL-ANIMALS - ITS ABSENCE IN ANEPHRIC INDIVIDUALS [J].
CARAMELO, C ;
FERNANDEZGALLARDO, S ;
MARINCAO, D ;
INARREA, P ;
SANTOS, JC ;
LOPEZNOVOA, JM ;
CRESPO, MS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (03) :789-796
[8]  
ELLISON EC, 1981, J SURG RES, V30, P241
[9]  
FERNANDEZMUNOZ D, 1985, AM J PHYSIOL, V249, pG236
[10]  
GOLFARB RD, 1985, J SURG RES, V38, P125